Non-Hodgkin Lymphoma by Clinical Course

Non-Hodgkin Lymphoma by Clinical Course — Trials · CancerIndex

Clinical trials

Registered studies

1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 172
Ph III recruiting: 8
Growth YoY: +32.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (209)

clinicaltrialsPublishedShowing 401–414 of 414 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	terminated	Phase 1	15	National Cancer Institute (NCI)NIH	1	Jan 25, 2013	clinicaltrials
NCT00064246	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder	completed	Phase 1 / Phase 2	28	National Cancer Institute (NCI)NIH	1	Jan 25, 2013	clinicaltrials